Source: Annual Congress 2009 - Pulmonary arterial hypertension



Rating:

Share or cite this content

Citations should be made in the following way:
R. J. Oudiz, B. Brundage, N. Galié, G. Simonneau, R. B. Barst, A. Elion-Mboussa, A. Beardsworth, H. A. Ghofrani (Torrance, Bend, New York City, Indianapolis, United States Of America; Bologna, Italy; Clamart, France; Giessen, Germany). Effect of once-daily tadalafil on exercise capacity and clinical deterioration with up to 68 weeks of treatment in patients with PAH. Eur Respir J 2009; 34: Suppl. 53, 1486

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of a 12 months oral sildenafil treatment in patients with severe pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 660s Year: 2006 Long-term effect of sildenafil on exercise capacity in COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 608s Year: 2007 Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Effect of oral sildenafil on physiological and sensory response to exercise in patients with mild-to-moderate COPD Source: Virtual Congress 2020 – Respiratory diseases, hypoxia and cardiovascular function Year: 2020 Effect of 8 and 12 weeks’ once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with COPD Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 LABA-LAMA combination is superior to LABA monotherapy in improving the cardiocirculatory responses to treadmill exercise in patients with moderate-to-severe COPD Source: Annual Congress 2010 - Exercise in COPD Year: 2010 Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study Source: Eur Respir J 2002; 20: Suppl. 38, 373s Year: 2002 Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Effect of sildenafil add-on to antifibrotic treatment in IPF patients Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Budesonide/formoterol improves exercise tolerance compared with placebo and formoterol in COPD patients Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance Year: 2009 Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006 Safety and tolerability of indacaterol over 52 weeks of treatment in COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Evening administration of tiotropium during combination therapy reduces night-symptoms in COPD patients Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Increased respiratory symptoms in COPD patients on withdrawal of therapy: evidence of long-term efficacy gains with formoterol turbuhaler Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 Comparative clinical-functional effectiveness and cardiological safety of short-acting combined broncholytics in 2 months basic therapy in COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 74s Year: 2007 Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008